ReviewEuropean review for medical and pharmacological sciences2008
New approaches to the treatment of opioid-induced constipation.
Review in European review for medical and pharmacological sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03060512 (A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Trial
- Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.Advances in therapy · 2016Trial
- Perioperative gut microbiota homeostasis and its interactions with anesthetic agents: recent advances.American journal of translational research · 2026Review
- Pathophysiological mechanisms, diagnostic innovations, and multimodal therapeutic strategies for slow transit constipation.BMC gastroenterology · 2025Review
- Observational
- Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Review
- Effect of Opioid Use on Immune Activation and HIV Persistence on ART.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.Journal of pain research · 2019Article
- Novel transmitters in brain stem vagal neurocircuitry: new players on the pitch.American journal of physiology. Gastrointestinal and liver physiology · 2018Review
- Opioid misuse in gastroenterology and non-opioid management of abdominal pain.Nature reviews. Gastroenterology & hepatology · 2018Review
- Incidence and Health Related Quality of Life of Opioid-Induced Constipation in Chronic Noncancer Pain Patients: A Prospective Multicentre Cohort Study.Pain research and treatment · 2018Article
- Site and mechanism of morphine tolerance in the gastrointestinal tract.Neurogastroenterology and motility · 2014Review
- Opiate-induced constipation related to activation of small intestine opioid μ2-receptors.World journal of gastroenterology · 2012Article
- Pharmacology of nonsteroidal antiinflammatory drugs and opioids.Seminars in interventional radiology · 2010Article
- Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Therapeutics and clinical risk management · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Opiates are indispensable for the treatment of moderate to severe pain. The gastrointestinal tract is one of the major victims of the undesired effects of opiates, because the enteric nervous system expresses all major subtypes of opioid receptors. As a result, propulsive motility and secretory processes in the gut are inhibited by opioid analgesics, and the ensuing constipation is one of the most frequent and troublesome adverse reactions. Many treatments involving laxatives, prokinetic drugs and opioid-sparing regimens have been explored to circumvent opioid-induced bowel dysfunction, but the outcome has in general been unsatisfactory. Specific antagonism of peripheral opioid receptors offers a more rational approach to the management of the adverse actions of opioid analgesics in the gut. This goal is currently addressed by the use of opioid receptor antagonists with limited absorption such as oral naloxone and by the development of peripherally restricted opioid receptor antagonists such as methylnaltrexone and alvimopan. These investigational drugs hold considerable promise in preventing constipation due to opiate treatment, whereas the analgesic action of opiates remains unabated. Postoperative ileus associated with opioid-induced postsurgical pain control is likewise ameliorated by the compounds. With this proof of concept, several phase III studies are under way to define optimal dosage, dosing regimen as well as long-term efficacy and safety of methylnaltrexone and alvimopan. In addition, there is preliminary evidence that these peripherally restricted opioid receptor antagonists may act as prokinetic drugs in their own right.
Indexed as
Identifiers
18924451PMC4370832W2164258267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.